

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC
Form 6-K
April 18, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending April 18, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons

I give below details of an increase in interests in Ordinary shares at a price
of GBP10.73 per share and Ordinary share ADRs at a price of \$43.32 per ADR in
GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned
persons, following the re-investment of the dividend paid to shareholders on 10
April 2008.

	Ordinary shares	ADRs
Dr M M Slaoui	25.97	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Mrs C E Bruck Slaoui	14.84	
Mr EJ Gray	26.52	
Mr D Learmouth	25.02	
Mr W C Louv		14.19
Mr S M Werner		14.47

The Company and the above named persons were advised of this information on 18 April 2008.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1) (a).

S M Bicknell
Company Secretary

18 April 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 18, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc